<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00579826</url>
  </required_header>
  <id_info>
    <org_study_id>10587</org_study_id>
    <secondary_id>CFEM345AUS45</secondary_id>
    <secondary_id>5R01CA122577-03</secondary_id>
    <nct_id>NCT00579826</nct_id>
  </id_info>
  <brief_title>Study of Breast Cancer Prevention by Letrozole in High Risk Women</brief_title>
  <official_title>Study of Breast Cancer Prevention by Letrozole in High Risk Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carol Fabian, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-institution double-blind placebo-controlled trial whose main objective is to
      determine if 6 months of letrozole (2.5 mg daily) can reduce proliferation as assessed by
      Ki-67 in high risk postmenopausal women on systemic hormone replacement therapy who have
      random periareolar fine needle aspiration (RPFNA) evidence of hyperplasia with atypia or
      borderline atypia, and a minimum Ki-67 of &gt;1.5%.

      The primary hypothesis is that proliferation and expression of other estrogen response genes
      will be favorably modulated by six months of letrozole relative to placebo without
      substantially increasing hot flashes or worsening overall quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subsequent to the 6 month RPFNA for assessment of biomarkers, toxicity and quality of life
      assessments, all women may receive optional open-label letrozole for an additional 6 months,
      followed by a third RPFNA and biomarker
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Proliferation Rate (Ki-67 by Immunocytochemistry) From Baseline to 6 Months</measure>
    <time_frame>Baseline to 6 Months</time_frame>
    <description>Change in proliferation rate (percent positively stained cells for Ki-67 antigen by immunocytochemistry) in benign breast epithelial cells acquired by random periareolar fine needle aspiration from women at high risk for the development of breast cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Change in Morphology by the Masood Score.</measure>
    <time_frame>Baseline to 6 Months</time_frame>
    <description>Masood score is a semi-quantitative index of increasing abnormality, thus higher values are worse. Range 6 to 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mammographic Density From Baseline to 6 Months..</measure>
    <time_frame>Baseline to 6 Months</time_frame>
    <description>Percent area of the breast considered to be at increased density, as determined by the computer program Cumulus..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Biomarkers Associated With Bone and Cardiovascular Health, Adverse Events, Breast Cancer Prevention Trial (BCPT) Symptom Check List, Hot Flash Score, General Fatigue Inventory, the Fibromyalgia Impact Questionnaire.</measure>
    <time_frame>6 Months, 12 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Letrozole, 2.5 mg daily for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, daily for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Letrozole 2.5 mg tablet daily. Then optional open label letrozole for another 6 months.</description>
    <arm_group_label>Letrozole</arm_group_label>
    <other_name>Letrozole(Femara)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet daily for 6 months then optional open label letrozole for 6 months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Post-menopausal women at high risk for development of breast cancer

          -  On a stable dose of hormone replacement therapy

          -  have cytomorphologic evidence of hyperplasia +/- atypia and Ki-67 expression &gt;1.5% in
             benign breast epithelial cells acquired by RPFNA

          -  Serum level of 25-OH vitamin D of at least 30 ng/ml prior to study entry

          -  Willing to have a repeat random periareolar fine needle aspiration (RPFNA) and
             mammogram at 6 months and 12 months (if participating in the open label portion of the
             study) following initiation of study drug

        Exclusion Criteria:

          -  Prior history of osteoporosis or osteoporotic fracture.

          -  Prior history of invasive breast cancer or other invasive cancer within five years
             from date of study entry.

          -  Current and chronic use of cyclooxygenase-2 (COX-2) specific inhibitors or NSAIDs

          -  Receiving treatment for rheumatoid arthritis or fibromyalgia

          -  Current history of poorly controlled migraines or perimenopausal symptoms

          -  Currently receiving other investigational agents.

          -  Receipt of more than 6 months of an aromatase inhibitor (anastrozole, exemestane,
             letrozole, etc.) at any time in the past.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carol J Fabian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2007</study_first_submitted>
  <study_first_submitted_qc>December 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2007</study_first_posted>
  <results_first_submitted>July 19, 2016</results_first_submitted>
  <results_first_submitted_qc>January 4, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 23, 2017</results_first_posted>
  <last_update_submitted>January 15, 2018</last_update_submitted>
  <last_update_submitted_qc>January 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Carol Fabian, MD</investigator_full_name>
    <investigator_title>Professor, Director Breast Cancer Prevention Unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Global results will be published.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Letrozole</title>
          <description>Letrozole, 2.5 mg daily for 6 months
Letrozole: Letrozole 2.5 mg tablet daily. Then optional open label letrozole for another 6 months.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo, daily for 6 months
Placebo: Placebo tablet daily for 6 months then optional open label letrozole for 6 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>6 Months</title>
              <participants_list>
                <participants group_id="P1" count="28">RPFNA for assessment for primary endpoint.</participants>
                <participants group_id="P2" count="25">RPFNA for assessment for primary endpoint.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24">Optional open label letrozole months 6-12; followed by RPFNA,</participants>
                <participants group_id="P2" count="23">Optional open label letrozole months 6-12; followed by RPFNA,</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled subjects</population>
      <group_list>
        <group group_id="B1">
          <title>Letrozole</title>
          <description>Letrozole, 2.5 mg daily for 6 months
Letrozole: Letrozole 2.5 mg tablet daily. Then optional open label letrozole for another 6 months.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo, daily for 6 months
Placebo: Placebo tablet daily for 6 months then optional open label letrozole for 6 months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="55"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.2" spread="8.3"/>
                    <measurement group_id="B2" value="44.7" spread="7.4"/>
                    <measurement group_id="B3" value="57.0" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>m</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.63" spread="0.09"/>
                    <measurement group_id="B2" value="1.64" spread="0.08"/>
                    <measurement group_id="B3" value="1.63" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.0" spread="11.2"/>
                    <measurement group_id="B2" value="73.6" spread="15.9"/>
                    <measurement group_id="B3" value="71.2" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.3" spread="5.0"/>
                    <measurement group_id="B2" value="27.9" spread="9.1"/>
                    <measurement group_id="B3" value="27.0" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age at menarche</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.6" spread="1.3"/>
                    <measurement group_id="B2" value="12.6" spread="1.2"/>
                    <measurement group_id="B3" value="12.6" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age at first live birth</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.5" spread="10.1"/>
                    <measurement group_id="B2" value="21.7" spread="11.1"/>
                    <measurement group_id="B3" value="21.4" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of prior breast biopsy</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>History of biopsy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No history of biopsy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of prior Ductal Carcinoma In Situ (DCIS) or Lobular Carcinoma in Situ (LCIS)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>History</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No History</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of relatives with breast cancer</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>With relatives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No relatives</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gail risk of developing breast cancer within 5 years</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.2" spread="3.9"/>
                    <measurement group_id="B2" value="3.4" spread="1.8"/>
                    <measurement group_id="B3" value="3.8" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Immunocytochemical expression of Ki-67</title>
          <description>Percent of breast epithelial cells staining positive for Ki-67 by immunocytochemistry.</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.5" spread="3.1"/>
                    <measurement group_id="B2" value="4.0" spread="2.8"/>
                    <measurement group_id="B3" value="4.2" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cytology</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hyperplasia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperplasia with borderline atypia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperplasia with Atypia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Masood Score</title>
          <description>Semi-quantitative cytology index score reflecting increasing abnormality, thus higher scores are worse. Range 6 to 24.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15" spread="0.9"/>
                    <measurement group_id="B2" value="15" spread="1.1"/>
                    <measurement group_id="B3" value="15" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Proliferation Rate (Ki-67 by Immunocytochemistry) From Baseline to 6 Months</title>
        <description>Change in proliferation rate (percent positively stained cells for Ki-67 antigen by immunocytochemistry) in benign breast epithelial cells acquired by random periareolar fine needle aspiration from women at high risk for the development of breast cancer.</description>
        <time_frame>Baseline to 6 Months</time_frame>
        <population>Subjects who complete initial 6-month period and have repeat RPFNA.</population>
        <group_list>
          <group group_id="O1">
            <title>Letrozole</title>
            <description>Letrozole, 2.5 mg daily for 6 months
Letrozole: Letrozole 2.5 mg tablet daily. Then optional open label letrozole for another 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, daily for 6 months
Placebo: Placebo tablet daily for 6 months then optional open label letrozole for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Proliferation Rate (Ki-67 by Immunocytochemistry) From Baseline to 6 Months</title>
          <description>Change in proliferation rate (percent positively stained cells for Ki-67 antigen by immunocytochemistry) in benign breast epithelial cells acquired by random periareolar fine needle aspiration from women at high risk for the development of breast cancer.</description>
          <population>Subjects who complete initial 6-month period and have repeat RPFNA.</population>
          <units>percentage of cells stained positive</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="2.8"/>
                    <measurement group_id="O2" value="-1.1" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.92</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Change in Morphology by the Masood Score.</title>
        <description>Masood score is a semi-quantitative index of increasing abnormality, thus higher values are worse. Range 6 to 24.</description>
        <time_frame>Baseline to 6 Months</time_frame>
        <population>Subjects who complete initial 6-month intervention and have a repeat RPFNA, thus a change from baseline to 6-months can be computed.</population>
        <group_list>
          <group group_id="O1">
            <title>Letrozole</title>
            <description>Letrozole, 2.5 mg daily for 6 months
Letrozole: Letrozole 2.5 mg tablet daily. Then optional open label letrozole for another 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, daily for 6 months
Placebo: Placebo tablet daily for 6 months then optional open label letrozole for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Change in Morphology by the Masood Score.</title>
          <description>Masood score is a semi-quantitative index of increasing abnormality, thus higher values are worse. Range 6 to 24.</description>
          <population>Subjects who complete initial 6-month intervention and have a repeat RPFNA, thus a change from baseline to 6-months can be computed.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="1.5"/>
                    <measurement group_id="O2" value="-1.1" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.96</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mammographic Density From Baseline to 6 Months..</title>
        <description>Percent area of the breast considered to be at increased density, as determined by the computer program Cumulus..</description>
        <time_frame>Baseline to 6 Months</time_frame>
        <population>Subjects who complete the initial 6-months intervention and have mammograms available for analysis at baseline and 6 months, thus a change can be computed.</population>
        <group_list>
          <group group_id="O1">
            <title>Letrozole</title>
            <description>Letrozole, 2.5 mg daily for 6 months
Letrozole: Letrozole 2.5 mg tablet daily. Then optional open label letrozole for another 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, daily for 6 months
Placebo: Placebo tablet daily for 6 months then optional open label letrozole for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mammographic Density From Baseline to 6 Months..</title>
          <description>Percent area of the breast considered to be at increased density, as determined by the computer program Cumulus..</description>
          <population>Subjects who complete the initial 6-months intervention and have mammograms available for analysis at baseline and 6 months, thus a change can be computed.</population>
          <units>percentage of breast at high densit</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="12.8"/>
                    <measurement group_id="O2" value="0.2" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.73</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Biomarkers Associated With Bone and Cardiovascular Health, Adverse Events, Breast Cancer Prevention Trial (BCPT) Symptom Check List, Hot Flash Score, General Fatigue Inventory, the Fibromyalgia Impact Questionnaire.</title>
        <time_frame>6 Months, 12 Months</time_frame>
        <posting_date>04/2018</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>duration of study agent</desc>
      <group_list>
        <group group_id="E1">
          <title>Letrozole, 2.5 mg Daily for 12 Months</title>
          <description>Letrozole, 2.5 mg daily for 6 months
Letrozole: Letrozole 2.5 mg tablet daily. Then optional open label letrozole for another 6 months.</description>
        </group>
        <group group_id="E2">
          <title>Placebo for 6 Months; Open Label Letrozole 2.5 mg Daily</title>
          <description>Placebo, daily for 6 months
Placebo: Placebo tablet daily for 6 months then optional open label letrozole for 6 months.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Tachycardia</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting/nausea</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Gallbladder necrosis</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney pain</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal mucositis/ cervical infection</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Wound complication</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bruce F. Kimler, Ph.D.</name_or_title>
      <organization>University of Kansas Medical Center</organization>
      <phone>913-588-4523</phone>
      <email>bkimler@kumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

